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Abstract: Pancreatic enzyme replacement therapy is currently the mainstay of treatment for 
nutrient malabsorption secondary to pancreatic insufficiency. This treatment is safe and has few 
side effects. Data demonstrate efficacy in reducing steatorrhea and fat malabsorption. Effective 
therapy has been limited by the ability to replicate the physiologic process of enzyme delivery 
to the appropriate site, in general the duodenum, at the appropriate time. The challenges include 
enzyme destruction in the stomach, lack of adequate mixing with the chyme in the duodenum, 
and failing to deliver and activate at the appropriate time. Treatment is begun when clinically 
significant malabsorption occurs resulting in steatorrhea and weight loss. Treatment failure 
is addressed in a sequential fashion. Current research is aimed at studying new enzymes and 
delivery systems to improve the efficiency of action in the duodenum along with developing 
better means to monitor therapy.
Keywords: exocrine pancreatic insufficiency, chronic pancreatitis, cystic fibrosis, pancreatic 
enzyme replacement therapy, lipase, lipids
Introduction
Normal pancreatic function ensures effective digestion and absorption of nutrients. 
Clinical exocrine pancreatic insufficiency occurs when secretions of the pancreas do 
not maintain normal digestive function, resulting in nutrient malabsorption and other 
symptoms such as diarrhea, which in turn affect quality of life and eventually result in 
malnutrition.1–3 The leading cause of pancreatic insufficiency is chronic pancreatitis, 
which is estimated to affect 0.4% to 5% of the world population.4 In children, 
however, the most common cause of pancreatic insufficiency is cystic fibrosis. The 
reported prevalence of exocrine pancreatic insufficiency in chronic pancreatitis and 
cystic fibrosis is 30% to 40% and 80% to 90% respectively.5 The use of oral therapy 
pre-dates the creation of the US Food and Drug Administration (FDA) in 1938, and 
currently enzyme replacement is the mainstay of therapy in patients diagnosed with 
malabsorption secondary to pancreatic insufficiency.
In order to manage patients effectively with malabsorption related to exocrine 
pancreatic insufficiency, an understanding of normal pancreatic physiology and 
pathophysiology is required. This review provides an overview of normal pancreatic 
function and the biochemistry of lipid digestion, along with the pathophysiologic 
mechanisms of disease that lead to malabsorption. Enzyme replacement therapy is 
reviewed including the pharmacokinetics, various preparations, dosing, and side effects. 
The inadequacy of current therapy has led to ongoing research, which is reviewed in Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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detail to examine how this has improved our understanding 
of lipid digestion and also the therapy we have to offer.
Normal exocrine pancreatic 
physiology
Composition and regulation  
of pancreatic fluid secretion
The exocrine pancreas plays a key role in the digestive 
function through the secretion of pancreatic juice consisting 
of numerous enzymes and of aqueous solution rich in sodium 
bicarbonate. Postprandial secretion can increase up to 1 to 
2 L per day.6–8 Three main types of enzymes are secreted to 
digest the ingested macronutrients: proteins (trypsinogen 1, 
2, and 3, chymotrypsinogen, proelastase 1 and 2, protease E, 
kallikreinogen, procarboxypeptidase A1, A2, B1, and B2), 
starchy foods (α-amylase), and lipids (Table 1).9–21 While 
lipases and amylase are secreted in the active form, proteases 
are secreted as pro-enzymes. Trypsinogen is converted to 
its active form trypsin in the duodenum by enterokinase, 
a protease secreted by the enterocytes, and trypsin in turn 
activates the other pancreatic proteases.
Enzyme content of pancreatic fluid changes according 
to different factors including age, gender, and diet. The 
pancreas reaches mature function by 2 years of age,22 and 
enzyme secretion is lower in full-term newborns and young 
infants than in adults.22–25 Pancreatic secretion in the elderly 
is decreased, with as little as 56% of young adult function 
maintained, but the clinical impact is controversial.26,27 
Men may have higher levels of secretion than women but 
the physiological relevance is not documented.27 Pancreatic 
fluid composition varies highly among individuals.7,28–31 
Amount and type of lipids consumed might explain in part 
this individual variability. Indeed, a 2-week high-fat/low-
carbohydrate diet is associated with a 4-fold higher pancreatic 
enzyme output in healthy humans compared with a diet rich 
in carbohydrates or proteins.32 Pancreatic lipase levels in 
the human duodenum vary with the quantity and the type 
of lipids ingested during a single meal.29,30,33–36 The rate of 
pancreatic enzyme degradation in the small intestinal lumen 
also varies among individuals.37 As a result of these variables, 
determining the exact enzyme level secreted by the normal 
human pancreas is difficult. Furthermore, varying methods 
used for collection and measurement of activity result in 
data that are not directly comparable. Pancreatic or duodenal 
juice is collected using solid or liquid meal,7,24,28,30,31,34–36,38,39 
or after direct hormonal stimulation8,22,23,40,41 or through 
baseline.24,39,42,43 Enzyme activity measurements are in general 
done under optimized assay conditions and do not indicate the 
real activity in vivo.28,38 Data are available as enzyme activities 
or output expressed as Units (U) per minute or U per hour, U 
per milliliter, or as milligrams of secreted enzymes (Tables 2 
and 3).7,8,22–24,29–31,34–36,40–45 To make the comparisons easier, 
enzyme activities are generally expressed as International 
Units (IU). One IU is defined as the amount of enzyme 
required to release 1 µmole of product from the used substrate 
per mL per min under the standard assay conditions.
There is a specific orchestration of the pancreatic 
fluid secretion during the fed state leading to appropriate 
enzyme delivery on demand in the duodenum. During the 
cephalic phase, orosensory perception of lipids seems to 
increase pancreatic secretion.46–49 During the gastric phase, 
digestion of proteins by pepsin and of triglycerides by 
gastric lipase generates amino acids and free fatty acids, 
respectively.50,51 When delivered through the pylorus, they 
become powerful stimulants of the cholecystokinin hormone 
(CCK) produced by the duodenal endocrine cells which 
stimulates pancreatic enzymes secretion and controls the 
gastric emptying rate.49 The acidic pH of the chyme entering 
the duodenum stimulates the release of secretin, which 
increases the secretion of water and bicarbonate ions from 
the pancreas.49 This gastric phase of digestion represents 
an important aspect in the overall postprandial regulation 
of pancreatic secretion that becomes abnormal after gastric 
surgery when gastric digestion and emptying are altered.52,53 
Table 1 Human pancreatic enzymes involved in lipid digestion
Enzyme name Specific substrate References
Pancreatic  
lipase
Triglycerides (lipid-droplet) 10,16,19
Pancreatic lipase  
related protein 1
Unknown
inhibitory effect of HPL  
(regulatory effect of TG  
digestion in the duodenum?)
11, 12
9
Pancreatic lipase  
related protein 2
Triglycerides  
(milk lipid-droplet)
Synergistic effect of HPL 
(regulatory effect of TG  
digestion in the duodenum?)
9 
9
Phospholipids 15,19
Galactolipids 13,18
Esters of vitamin A 17
Carboxyl ester lipase Esters of lipid-soluble vitamins 14
Esters of cholesterol 14
Triglycerides, diglycerides,  
monoglycerides
14
Phospholipids 14
Ceramides 14
Phospholipase A2 Phospholipids 20
Abbreviations: HPL, human pancreatic lipase; TG, triglycerides.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Baseline and postprandial activity of the main pancreatic enzymes in healthy humansa
Activity (Units)b Collection condition Method of measurement Age, number, references
Full-term infants
Lipase 1061 ± 101 CCK + secretin Olive oil emulsion, pH 9, 25°Cm 7 mo, n = 18, Palasciano41
982 (49–978) CCK + secretin Olive oil emulsion, pH 9.1, 37°Cm At birth, n = 8, Zoppi23
20/50/600 Baseline Olive oil emulsion, pH 8 1 d/1 mo/2 yr, n = 15, Lebenthal22
20/50/1400 CCK Olive oil emulsion, pH 8 1 d/1 mo/2 yr, n = 15, Lebenthal22
1071 ± 143 CCK + secretin Olive oil emulsion, pH 9.1, 37°Cm 10–144 mo, n = 7, Moreau40
Phospholipase 16.7 ± 1.9 CCK + secretin Egg-yolk lipoprotein, pH 8, 40°C 7 mo, n = 18, Palasciano41
Trypsin 451 (27–1328) µg CCK + secretin BAEE, pH 8, 25°Cn At birth, n = 8, Zoppi23
180/325/180 Baseline BAPNA, pH 8.2, 25°Co 1 d/1 mo/2 yr, n = 15, Lebenthal22
170/280/400 CCK BAPNA, pH 8.2, 25°Co 1 d/1 mo/2 yr, n = 15, Lebenthal22
Chymotrypsin 93 ± 9 CCK + secretin ATEE, pH 7.9, 25°C 7 mo, n = 18, Palasciano41
5–7.5–12.5 Baseline BTEE, pH 7.2–8.0, 30°C 1 d/1 mo/2 yr, n = 15, Lebenthal22
7–9–25 CCK BTEE, pH 7.2–8.0, 30°C 1 d/1 mo/2 yr, n = 15, Lebenthal22
Amylase 22 (2–37) CCK + secretin Starch, pH 6.9, 25°C At birth, n = 8, Zoppi23
0 Baseline or CCK Starch 1 d/1 mo, n = 15, Lebenthal22
225 Baseline Starch 2 yr, n = 15, Lebenthal22
300 CCK Starch 2 yr, n = 15, Lebenthal22
Adults
Lipase 1454 ± 95 CCK + secretin Olive oil emulsion, pH 9, 25°Cm 42–46 yr, n = 38, Palasciano41
839 ± 429 Baseline Olive oil emulsion, pH 9, 25°Cm 20–55 yr, n = 7, Mott43
74–1674 Test mealc Olive oil emulsion, pH 9.1, 37°Cm nd, n = 15, Braganza7
84–1127 Baseline Tributyrin, pH 8, 25°C 22–36 yr, n = 7, Fredrikzon24
750–1125 Test meald Tributyrin, pH 8, 25°C 22–36 yr, n = 7, Fredrikzon24
1200 ± 459 CCK + cerulein (PPJ)* Olive oil emulsion, pH 9, 25°Cm 29–58 yr, n = 7, Escourrou8
977 ± 282 CCK + cerulein Olive oil emulsion, pH 9, 25°Cm 29–58 yr, n = 7, Escourrou8
1969 ± 241 Test meale Olive oil emulsion, pH 9, 25°Cm 20–28 yr, n = 26, Bozkurt44
1020 ± 128 CCK + secretin Olive oil emulsion, pH 9.1, 37°Cm 25–71 yr, n = 15, Moreau40
200–2400 Test mealf Tributyrin, pH 8.0, 37°C 22–42 yr, n = 15, Carrière34
600–1400 Test mealg Triolein emulsion, pH 9.0, 37°Cp 19–24 yr, n = 7, Armand29
200–1000 Test mealh Tributyrin, pH 7.5, 27°C 38–58 yr, n = 18, Yago36
772,000 ± 200,000/240 min Test meali Olive oil emulsion, pH 8.8, 30°Cq 22–40 yr, n = 6, Schwizer31
1105 ± 360 Baseline Triolein emulsion, pH 9, 25°C 22–26 yr, n = 14, Keller39
4740 ± 800 Test mealj Triolein emulsion, pH 9, 25°C 22–26 yr, n = 14, Keller39
1500–4000 Test mealk Tributyrin, pH 8.0, 37°C 22–26 yr, n = 8, Armand30
2000–7000 Test meall Tributyrin, pH 8.0, 37°C 21–25 yr, n = 6, Carrière35
CEL 3.9–29.5 Baseline p-nitrophenyl acetate, pH 7.4 22–36 yr, n = 7, Fredrikzon24
10–15 Test meald p-nitrophenyl acetate, pH 7.4 22–36 yr, n = 7, Fredrikzon24
Phospholipase 24.44 ± 1.53 CCK + secretin Egg-yolk lipoprotein, pH 8, 40°C 42–46 yr, n = 38, Palasciano41
Trypsin 13–138 Test mealc TAME, pH 7.7, 37°C nd, n = 15, Braganza7
25–50 Test mealh BAEE, pH 7.9, 27°C 38–58 yr, n = 18, Yago36
Chymotrypsin 147 ± 11 CCK + secretin ATEE, pH 7.9, 25°C 42–46 yr, n = 38, Palasciano 197941
65 ± 17 Baseline ATEE, pH 7.9, 25°C 20–55 yr, n = 7, Mott43
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Table 3 Postprandial output expressed as amount of the main pancreatic enzymes in the duodenal lumen in healthy adult humansa
Outputb Collection condition Method of measurement Age, number, references
Lipase 54.9 ± 10.7c,d Liquid test mealh Tributyrin, pH 8.0, 37°C 22–42 yr, n = 15, Carrière34
88.2 ± 25c,d Liquid test mealh Tributyrin, pH 8.0, 37°C 22–42 yr, n = 15, Carrière34
245 ± 22c,e Liquid test meali Triolein emulsion, pH 8.0 23–30 yr, n = 6, Borovicka33
442 ± 87d,f Liquid test mealj Enzyme immunoassay 22–40 yr, n = 6, Schwizer31
253 ± 95g Liquid test mealk ELiSA 20–50 yr, n = 3, Carrière38
203 ± 96g Liquid/solid test meall ELiSA 20–50 yr, n = 7, Carrière38
416 ± 142c,e Liquid/solid test mealm Tributyrin, pH 8.0 21–25 yr, n = 6, Carrière35
Chymotrypsin 133 ± 50c,e Liquid/solid test mealm ATEE, pH 7.5, 37°C 21–25 yr, n = 6, Carrière35
Amylase 167 ± 133c,e Liquid/solid test mealm Starch, pH 6.9, 30°C 21–25 yr, n = 6, Carrière35
Notes: aSamples are duodenal aspirates; bOutput is expressed as total mg of proteins measured by immunoassay or specific ELISA test or cestimated using the known specific 
activity of enzymes (for pure human pancreatic lipase 8000 iU/mg on tributyrin or 1785 iU/mg on triolein), and for d1-h period, e3-h period, f4-h period, g90-min period; For 
lipase activity measurement the authors also used a different concentration and type of bile salts that was not reported in the “Method of measurement.” Test meals: hFormula 
Shak iso (500 mL, 14 g proteins [P], 12.5 g lipids [L], 52 g carbohydrates [C]); iFormula Ensure (500 mL, 16.8 g P, 13.4 g L, 53.4 g C); jFormula 10% intralipid (500 mL, 550 kcal); 
kFormula Shak iso (500 mL, 19 g P, 17 g L, 69 g G); lmixed solid/liquid meal (700 mL, 80 g string beans, 90 g beef meat, 70 g French fries, 10 g butter); mMixed solid/liquid meal 
(700 mL, 80 g string beans, 90 g beef meat, 70 g fried potatoes, 10 g butter, 15 mL olive oil).
Abbreviations: ATEE, N-acetyl-L-tyrosine ethyl ester; ELiSA, enzyme-linked immunosorbent assay.
Table 2 (Continued)
Activity (Units)b Collection condition Method of measurement Age, number, references
113 ± 56 CCK + cerulein (PPJ)* ATEE, pH 7.9, 25°C 29–58 yr, n = 7, Escourrou8
109 ± 30 CCK + cerulein ATEE, pH 7.9, 25°C 29–58 yr, n = 7, Escourrou8
30–100 Test meall ATEE, pH 7.5, 37°C 21–25 yr, n = 6, Carrière35
50–75 Test mealh ATEE, pH 7.9, 27°C 38–58 yr, n = 18, Yago36
Amylase 31–840 Test mealc Starch, pH 7, 30°C nd, n = 15, Braganza7
161 ± 68 CCK + cerulein (PPJ)* Starch 29–58 yr, n = 7, Escourrou8
143 ± 36 CCK + cerulein Starch 29–58 yr, n = 7, Escourrou8
1.5–4.2 Test mealh Starch, pH 6.9 38–58 yr, n = 18, Yago36
2.5–16 Test meall Starch, pH 6.9, 30°C 21–25 yr, n = 6, Carrière35
Notes: aThe majority of the samples were duodenal aspirates except for * which were pure pancreatic juice (PPJ); bUnits are expressed per mL of fluid except otherwise 
indicated. 1 iU of lipase activity corresponds to 1 µmole free fatty acid released/min; 1 U of phospholipase activity corresponds to 1 NaOH µequivalent liberated/min; 1 iU of 
CEL activity corresponds to 1 µmol p-nitrophenol produced/minute; 1 iU of amylase activity corresponds to 1 µmole of maltose equivalent released/min; 1 iU of trypsin activity 
corresponds to 1 µmole of substrate hydrolyzed/min or n1 U corresponds to 1 µg/ml or o1 U corresponds to 1 nanomol of p-nitroaniline produced/min; 1 iU of chymotrypsin 
activity corresponds to 1 µmole of substrate hydrolyzed/min; For lipase activity measurement the authors used also different concentration and type of bile salts that was not 
reported in the “Method of measurement”. Test meals: cLundh Borgström test meal (500 mL, 5% proteins [P], 6% lipids [L], 15% carbohydrates [C]); dTest meal (450–850 mL 
of cow milk plus cream for a lipid load of 1 g/kg body weight); eLundh test meal (300 mL, 5% P, 6% L, 15% C); fFormula Shak iso (500 mL, 14 g P, 12.5 g L, 52 g C); gLiquid meal 
(400 mL, 1 egg, 1 egg white, 70 g olive oil, 70 g sucrose); hLiquid meal (200 mL, 8.5 g P, 7 g L, 26.5 g C); iFormula 10% intralipid (500 mL, 550 kcal); jFormula (300 mL, 11 g P, 
10 g L, 41 g C); kFormula (500 mL, 34 g P, 50 g L, 50 g C); lMixed solid/liquid meal (700 mL, 80 g string beans, 90 g beef meat, 70 g fried potatoes, 10 g butter, 15 mL olive oil); 
Substrate: mOlive oil emulsion stabilized by Arabic gum; pTriolein emulsion stabilized by Arabic gum; qOlive oil emulsion stabilized by acacia gum.
Abbreviations: ATEE, N-acetyl-L-tyrosine ethyl ester; BAEE, N-benzoyl-L-arginine ethyl ester; BAPNA, benzoyl-DL-arginine-p-nitroaniline; BTEE, N-benzoyl-DL-tyrosine 
ethyl acetate ester; CEL, carboxyl ester lipase; CCK, cholecystokinin; TAME, p-toluene sulfonyl-L-arginine methyl ester; PPJ, pure pancreatic juice.
During the intestinal phase, enterohormones, such as CCK, 
together with neurotransmitters and neuropeptides further 
stimulate pancreatic secretion.49,54 Thus, digestive pancreatic 
enzyme response to a meal follows a specific pattern in which 
the degree and duration depend on nutrient composition, 
caloric content, and physical properties of the meal through 
hormonal and neural regulations; enzyme secretion into the 
duodenum increases quickly reaching peak output within 
the first 20 to 60 minutes postprandially, then decreasing 
to a stable level before reaching an interdigestive level at 
the end of the digestive period, ie, about 4 hours after meal 
intake.27
Role of pancreatic enzymes in lipid 
bioavailability
Pancreatic juice plays a key role in the digestion of all 
macronutrients, but is most crucial for lipid digestion. Protein 
digestion begins in the stomach with the concomitant action 
of hydrochloric acid and pepsin, continues with pancreatic 
proteases in the duodenum, and finishes with numerous 
brush border peptidases located all over the small intestine.50 
Starch digestion begins in the mouth with salivary amylase, 
continues with pancreatic amylase, and ends with several 
intestinal brush border oligosaccharidases.50 In contrast, the 
majority of lipid digestion and absorption occurs between Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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the pylorus and the ligament of Treitz. Prior to this step, 5% 
to 40% of the dietary triglyceride acyl chains are released 
in the stomach by gastric lipase,29,30,34,51,55,56 which continues 
its action in the duodenum together with pancreatic lipase 
until these enzymes are degraded by pancreatic proteases.34 
The human pancreatic lipase (HPL) specifically cleaves the 
outer sn-1 and sn-3 esters on the triglyceride molecules and 
generates two free fatty acids and a 2-monoglyceride.10,19 
This lipase needs a specific cofactor, colipase, to anchor 
at the lipid–droplet surface containing phospholipids and 
surrounded by bile lipids (bile salts and phospholipids).16,58 
Although a pH of 8 to 9 appears to be optimal for this 
lipase activity in vitro, bile salts allow the enzyme to work 
efficiently at a pH of 6 to 6.5 in vivo.10,29,35 HPL is responsible 
for the hydrolysis of 40% to 70% of triglycerides.29,30,34 The 
pancreatic lipase related 1 protein (hPLRP1) has no known 
lipolytic activity11,12,16 but inhibits to some extent lipolysis 
of milk triglycerides by HPL.9 The pancreatic lipase-related 
2 protein (hPLRP2) exhibits a broad substrate specificity 
hydrolyzing milk triglycerides in a synergistic effect with 
HPL,9 phospholipids,15,16,19 galactolipids,13,18 and esters of 
lipid-soluble vitamins.17 Carboxyl ester lipase (CEL) (also 
secreted by mammary gland cells as bile salt-stimulated 
lipase, (BSSL)) will hydrolyze triglycerides, diglycerides, 
phospholipids, and esters of lipid-soluble vitamins and of 
cholesterol.14 Of note, hPLRP2, which is highly expressed in 
early life, plays an important role in lipid digestion in infants 
fed human milk,59,60 along with BSSL.59 Phospholipase 
A2 hydrolyzes phospholipids to lysophospholipids20 which 
is essential for an optimal absorption of lipid nutrients.61 
Products generated during lipolysis are solubilized in bile 
salts–mixed micelles and liposomes (vesicles) which allow 
absorption across the intestinal villi.62 Once absorbed, 
the digested lipids are converted back to triglycerides, 
phospholipids, and esters of cholesterol and of lipid-soluble 
vitamins, then packaged as chylomicrons and transported 
through the thoracic duct into the systemic circulation for 
delivery to various sites throughout the body.61,63
Exocrine pancreatic insufficiency
Clinical presentation and diagnosis
Exocrine pancreatic insufficiency (EPI) is largely a clinical 
diagnosis. A patient with a known cause of pancreatic 
insufficiency who presents with weight loss and fatty diarrhea 
is usually begun on treatment without extensive testing. As 
up to 20% of patients with chronic pancreatitis resulting in 
insufficiency will present with no history of pain suggestive 
of pancreatitis, steatorrhea may be the presenting complaint.64 
The diagnostic options include indirect measures (ie, 72-hour 
fecal fat and fecal elastase) or direct measures (ie, secretin–
cerulein or secretin–pancreozymin tests). Steatorrhea is 
classically defined as at least 7 g of fecal fat over 24 hours, 
in the context of a 72-hour stool test while on 100 g of fat 
daily;65 however, quantification of fecal fat is inconvenient 
and difficult. With reasonable clinical suspicion, a positive 
spot stool test may be adequate to detect steatorrhea66 but will 
not allow monitoring of response to therapy. Fecal elastase 
testing may be used to demonstrate a lack of endogenous 
enzyme. It has been found that fecal elastase is 72% sensitive 
for severe pancreatic insufficiency and 90% specific. It does 
have lower sensitivity with milder steatorrhea, and is not as 
useful in diabetics, as fecal elastase decreases with increased 
duration of diabetes.67–69 In contrast to the above indirect 
measurements of pancreatic function, direct measurements 
with the secretin–cerulein or secretin–pancreozymin tests 
are the gold standard for accurate assessment of the exocrine 
function of the pancreas.69,70 However, the limitations of the 
direct functional tests are that they are usually performed 
only at specialized centers, and they are time consuming 
and expensive.69
Patients usually will present for evaluation when ,10% 
of exocrine pancreatic function remains, which results in lipid 
malabsorption.3,71 Steatorrhea (frothy, foul smelling, buoyant 
stools), weight loss, abdominal discomfort, and abdominal 
swelling are the common presenting symptoms and are 
related to the inadequate lipid digestion. Even with significant 
pancreatic insufficiency, protein and starch digestion are 
usually maintained at a normal physiologic level. However, 
once pancreatic insufficiency progresses, lipid malabsorption 
becomes the overriding problem and cause of many of the 
clinical symptoms and nutritional deficiencies. Consequences 
of abnormal lipid digestion lead to malnutrition, with 
malabsorption of lipid-soluble vitamins (A, D, E, K), depleted 
micronutrients, and decreased circulating lipoproteins.3,72–74 
Exocrine pancreatic insufficiency itself can cause or exacerbate 
motility disorders. There are alterations in neurohormonal 
regulation in gastrointestinal motility; specifically, the 
production of CCK and of pancreatic polypeptide are adversely 
affected by undigested food in the intestines, which can lead 
to rapid gastric emptying and altered antroduodenal and 
gallbladder motility. In untreated EPI, patients are noted to 
have shorter fed patterns, and a faster small intestinal transit 
that is largely reversed with enzyme therapy.71 The severity of 
such motility disorders is often related to the severity of the 
pancreatic insufficiency, and this can often be corrected with 
enzyme replacement therapy.75–80Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
60
Fieker et al
Causes of lipid maldigestion  
and malabsorption
There are various causes of pancreatic insufficiency resulting in 
malabsorption (Table 4), and for some the status of pancreatic 
enzyme levels has been documented (Table 5).23,24,35,40,42,44,45,71 
Chronic pancreatitis (CP) and cystic fibrosis (CF) are the 
most common causes of irreversible pancreatic insufficiency. 
Diabetes may also result in exocrine insufficiency.81 In 
contrast, decreased production of pancreatic lipase without 
glandular destruction is associated with Celiac sprue, 
Crohn’s disease, and Shwachman–Diamond syndrome.2,71 
Reversible pancreatic insufficiency has been reported in 
premature infants due to developmental immaturity.22–25 The 
pancreas will gain complete function in infants at 2 years of 
age.22 Other causes of lipid maldigestion are blockage of the 
pancreatic duct, and surgical resection.2,5,71
Motility disorders that result in rapid gastric emptying and 
decreased small intestinal transit time may also be associated with 
malabsorption due to inadequate lipid digestion. Rapid transit 
causes poor mixing of food together with bile and pancreatic 
enzymes, further reduces contact time with the small intestine 
leading to impaired digestion and absorption, and affects the 
stimulation of pancreatic function.5,71 For instance, gastrectomy 
alters gastric emptying, which reduces lipase production 
because chyme rapidly bypasses the duodenum resulting in 
reduced stimulation of duodenal hormones that normally 
stimulate the pancreas to release enzymes.5 Of note, some 
studies of steatorrhea after gastrectomy have not demonstrated 
a benefit of pancreatic enzyme supplementation.82
It is also important to be aware that diabetic patients 
may also suffer from exocrine insufficiency as a result of 
endocrine failure, presenting as either classic steatorrhea 
or more subtly as brittle diabetes.81 Studies have reported 
that exocrine dysfunction occurs in up to 43% of insulin-
dependent diabetics, but its severity is typically mild to 
moderate, and only 1% of these patients require therapy.83,84 
Mild to moderate exocrine insufficiency was reported in 
30% of type 2 diabetics, 19% of whom were suffering from 
severe insufficiency.85 These studies raised the question of 
the clinical significance of EPI in diabetic patients, which 
would potentially raise health care costs to these patients 
if expensive enzyme replacement therapy were required. 
A thorough investigation studied pancreatic function in 
type 1 diabetic patients with a secretin–cerulein test, fecal 
fat stimulation, and 2 fecal elastase tests to determine 
the accuracy of previous studies and define the clinical 
significance. In this study, 33% of type 1 diabetics were found 
to have mild to moderate pancreatic insufficiency, but none of 
the patients had lipase levels ,10% of normal, which would 
necessitate enzyme replacement. It was concluded that fecal 
elastase or fecal fat levels were not reliable diagnostic tools 
for diabetes. Moreover, the majority of these patients had 
steatorrhea not related to pancreatic function, but rather to 
bacterial overgrowth.69 Although diarrhea and steatorrhea 
are often multifactorial in diabetics, and the significance 
of exocrine insufficiency in diabetics is still under study, 
physicians should be aware of the association and have a low 
threshold to test for this entity in diabetics.81
The pathophysiology of EPi caused  
by glandular destruction in CP and CF
Irreversible pancreatic insufficiency is mainly observed in 
CP and CF.4,5 In CP, long-standing inflammation with fibrosis 
results in destruction of acinar cells. A variety of proposed 
pathogenic mechanisms has been described. Alcohol is a 
common cause of chronic pancreatitis, and it has been shown 
to be directly toxic to the pancreatic acinar cells. It produces 
cytoplasmic lipid accumulation ultimately leading to fibrosis 
and gland failure.57 Moreover, chronic use of alcohol can 
cause pancreatic secretions to be more lithogenic, which 
results in stone formation and pancreatic duct obstruction. 
The contact of stones with the duct lumen will ultimately lead 
to a cascade of events, which includes ulceration, scarring, 
stasis, further stone formation with eventual atrophy, and 
fibrosis.86,87 In contrast to de novo stone formation as a 
result of alcohol consumption, repeated attacks of acute 
pancreatitis from various causes including alcohol will result 
in peri-ductular scarring, which leads to duct obstruction 
Table 4 Etiologies of exocrine pancreatic insufficiency
Mechanism Etiology
Decreased lipase production and delivery, increase lipase destruction Chronic pancreatitis, cystic fibrosis, diabetes
Pancreatic duct obstruction Periampullary tumor, pancreatic head cancer, iPMN, benign tumors
Decreased endogenous lipase stimulation and production Celiac disease, Crohn’s disease, Shwachman–Diamond syndrome
Motility disorders (decrease contact time, interaction with chyme,  
decrease stimulation of pancreatic enzymes)
Gastrectomy, gastric bypass, extensive small bowel resection
Abbreviation: iPMN, intraductal papillary mucinous neoplasm.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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with stasis and a similar cascade of events that will lead to 
glandular fibrosis.88,89 Oxidized byproducts of metabolism are 
produced in the liver and secreted in bile, and it is proposed 
that this results in oxidative stress as the bile is refluxed into 
the pancreatic ducts. Oxidative stress has also been attributed 
to high levels of dietary lipids or alcohol.90–92 Also described 
is an immunologic response that results in an attack on the 
ductal epithelium, an autoimmune-like reaction, resulting in 
scarring and fibrosis.93 A recently proposed theory, the SAPE 
(sentinel acute pancreatitis event) hypothesis, combines 
a number of the above-described pathogenic mechanisms 
leading to chronic pancreatitis. It suggests an initial event 
of acute pancreatitis that leads to an inflammatory response 
secondary to an insult such as alcohol or oxidative stress. 
If this insult is removed, tissue repair occurs. If the insult is 
not removed, proinflammatory cytokines activate pancreatic 
stellate cells resulting in chronic pancreatitis with fibrosis and 
tissue destruction. This ultimately leads to reduced secretion 
of adequate amounts of lipase, giving rise to pancreatic 
insufficiency.94,95
In CF, the mutation of the CFTR (cystic fibrosis 
transmembrane conductance regulator) protein results in 
abnormal sodium and chloride transport. Normally, luminal 
chloride is exchanged for bicarbonate, which allows for an 
alkaline environment within the lumen, allowing highly 
  concentrated proteins to remain in the soluble state. With 
mutant CFTR protein, the net result is abnormally viscous 
secretions and an acidic lumen, resulting in ductal   obstruction. 
  Prolonged obstruction results in tissue destruction by retained 
  proteolytic enzymes, fibrosis, fatty replacement, cyst 
formation, and eventual exocrine insufficiency.3,96
The initial effect of acinar destruction is decreased pan-
creatic enzyme production (Table 5). However, lipid diges-
tion can be maintained to reach an absorption rate of 20% to 
80% due to the action of gastric lipase secreted by the fundic 
mucosa of the stomach;51 indeed this lipase output is normal 
or higher in CP and CF patients,35,51,97 and its action take place 
both in the stomach and in the duodenum, being favored by 
a low level of pancreatic proteases and low intraduodenal 
pH.51 But the lipolysis rate reached by the gastric lipase is 
Table 5 Baseline or postprandial activity of the main pancreatic enzymes in transitory or irreversible pancreatic insufficiencya
Activity (Units)b Collection condition Method of measurement Age, number, references
Preterm infants
Lipase 378 (145–1121) CCK + secretin Olive oil emulsion, pH 9.1, 37°Cf 32–34 wk GA, n = 36, Zoppi23
149–586 Baseline Tributyrin, pH 8, 25°C 16–38 d, n = 7, Fredrikzon24
50–100 Test mealc Tributyrin, pH 8, 25°C 16–38 d, n = 7, Fredrikzon24
8.4–15.1 Baseline Triolein, pH 7.4 23–26 d, n = 35, Boehm42
CEL 12.2–32.9 Baseline p-nitrophenyl acetate, pH 7.4 16–38 d, n = 7, Fredrikzon24
2.5–9 Test mealc p-nitrophenyl acetate, pH 7.4 16–38 d, n = 7, Fredrikzon24
Trypsin 292 (0–682) CCK + secretin BAEE, pH 8, 25°C 32–34 wk GA, n = 36, Zoppi23
5.2–8.6 Baseline TAME, pH 8.1 23–26 d, n = 35, Boehm42
Amylase 4.3 (0–5.1) CCK + secretin Starch, pH 6.9, 25°C 32–34 wk GA, n = 36, Zoppi23
CF infants
Lipase 7 ± 3 CCK + secretin Olive oil emulsion, pH 9.1, 37°Cf 1–30 mo, n = 6, Moreau40
(PS) 6300–28,200 iU/kg/h CCK + secretin Tributyrin, pH 8.5, 37°C 0.5–17 yr, n = 5, Nouri45
(Pi) 0 CCK + secretin Tributyrin, pH 8.5, 37°C 12–13 yr, n = 2, Nouri45
Phospholipase (PS) 25–33 mmol/kg/h CCK + secretin 31P NMR spectra, pH 7.44, 37°C 0.5–17 yr, n = 5, Nouri45
(Pi) 0 CCK + secretin 31P NMR spectra, pH 7.44, 37°C 12–13 yr, n = 2, Nouri45
Adult Mild-EPI
Lipase 458 ± 83 Test meald Olive oil emulsion, pH 9, 25°Cf 21–73 yr, n = 15, Bozkurt44
2000–6000 Test meale Tributyrin, pH 8.0, 37°C 40–60 yr, n = 5, Carrière35
Adult Severe-EPI
Lipase 52 ± 31 Test meald Olive oil emulsion, pH 9, 25°Cf 21–73 yr, n = 18, Bozkurt44
480 ± 125 CCK + secretin Olive oil emulsion, pH 9.1, 37°Cf 16–72 yr, n = 13, Moreau40
160 Test meale Tributyrin, pH 8.0, 37°C 43–61 yr, n = 7, Carrière35
Notes: aSamples are duodenal aspirates; bUnits are expressed per mL of fluid except otherwise indicated. 1 IU of lipase activity corresponds to 1 µmole free fatty acid 
released/min; 1 U of phospholipase activity is expressed as mmoles of lysophospatidylcholine produced/kg body weight in total volume of duodenal juice secreted for 1 hour; 
1 iU of CEL activity corresponds to 1 µmol p-nitrophenol produced/min; 1 iU of amylase activity corresponds to 1 µmole of maltose equivalent released/min; 1 iU of trypsin 
activity corresponds to 1 µmole of substrate hydrolyzed/min (TAME) or 1 U of trypsin activity corresponds to 1 µg/mL (BAEE); For lipase activity measurement the authors 
used also different concentration and type of bile salts that was not reported in the “Method of measurement”.
Test meals: cHuman milk; dLundh test meal (300 mL, 5% proteins [P], 6% lipids [L], 15% carbohydrates [C]); eMixed solid/liquid meal (700 mL, 80 g string beans, 90 g beef 
meat, 70 g fried potatoes, 10 g butter, 15 mL olive oil); fOlive oil emulsion stabilized by Arabic gum.
Abbreviations: BAEE, N-benzoyl-L-arginine ethyl ester; CCK, cholecystokinin; CEL, carboxyl ester lipase; PI, pancreatic insufficient; PS, pancreatic sufficient; TAME, p-toluene 
sulfonyl-L-arginine methyl ester.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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not always sufficient to make up for the lack of pancreatic 
lipase.5 As continued glandular destruction occurs in CP and 
CF, the ductules are affected causing inadequate bicarbonate 
production and resulting in an inability to neutralize acidic 
chyme.3 Along with decreased pancreatic bicarbonate secre-
tion, gastric acid production is increased in certain conditions 
associated with pancreatic insufficiency, notably advanced 
CP and CF.5,35,97–100 Consequently the intraduodenal pH will 
be acidic (3 to 5)35,98 and will lead to enzyme inactivation 
and bile salt denaturation.5,71,98 The bile salt pool is even 
more reduced by decreased enterohepatic circulation of bile 
secondary to impaired ileal mucosa absorption.101 As bile 
salts are required to solubilize the lipolytic products within 
the intestinal lumen, this process further impairs lipid diges-
tion and absorption.3,61
Pancreatic enzyme replacement 
therapy
Formulations and pharmacokinetics
The goal of supplemental enzyme therapy in EPI is to 
minimize nutrient malabsorption, especially of lipids, and to 
do this it is important to achieve an adequate concentration 
of active pancreatic enzymes in the duodenum at the same 
time that food is delivered.3,71 Attempting to replicate this 
physiologic process requires resistance to gastric inactivation 
and delivery of active enzyme at the site where digestion 
is required, the duodenum. The composition and various 
formulations of pancreatin and pancrelipase affect their use 
and ability to deliver appropriate amounts of active enzyme 
to the duodenum. Pancreatin, a crude mixture, is derived 
from swine or ox pancreas, and each milligram contains 
no less than 2 USP (United States Pharmacopeia) units of 
lipase and 25 USP units of amylase and protease activity. 
Pancrelipase is obtained from swine pancreas and is a 
more concentrated and purified enzyme preparation. Each 
milligram contains no less than 24 USP units of lipase and 
100 USP units of amylase and protease activity. Because of 
its higher enzyme content, pancrelipase formulations are 
favored over pancreatin preparations.3 A variety of delivery 
agents has been developed in attempts to increase resistance 
to destruction, and enable delivery to sites where lipid 
digestion is physiologic, ie, the duodenum. The uncoated 
formulations are susceptible to acidic breakdown in the 
stomach and are currently used largely in clinical practice to 
treat the pain of chronic pancreatitis and not malabsorption.102 
Enteric-coated preparations were designed to avoid 
inactivation in the stomach, as the enzyme is protected from 
the acidic environment by the coating, and then dissolves in 
the duodenum when pH exceeds 5 to 5.5.3 A wide range of 
polymers, natural (carboxylmethyl or succinate high amylose 
starch) or synthetic (methacrylate copolymers, polymer 
cellulose acetate phtalate, hydroxyl propyl methyl cellulose 
phtalate), with different pH sensitivity, have been examined as 
excipients to circumvent the gastric inactivation of enzymes 
and to control the timing and location of their release in 
enteric-coated preparations.103,104 They are supposed to allow 
uniform mixing in the stomach without releasing their content 
and timely delivery to the duodenum for digestion to proceed. 
But effective delivery and release are difficult to achieve 
because the pH in the stomach can fluctuate from 6, owing to 
the buffering capacity of the meal, down to 2 during the fed 
state,98 and the duodenal pH ranges from 4 to 6,35,105 with high 
individual variability. In fact, dissolution characteristics of 
excipients are quite different in terms of optimum pH (5 or 5.8 
for example) and time (49 to 71 minutes for the half-time of 
release).106–108 As a result, enteric-coated microspheres are not 
bioequivalent in vitro, and probably not in vivo, depending 
on the pH of the duodenal content.106–108
Early enteric-coated formulations did not empty into the 
duodenum as quickly as smaller food particles, impairing 
their ability to aid in digestion. Newer formulations use the 
enteric-coated microsphere technology that allows a smaller, 
yet stable delivery system. Studies have demonstrated that the 
size of the particles or the microspheres affect the delivery to 
the duodenum, and that particles of smaller size empty more 
quickly, with 1.4 mm being the optimal size.109 In theory, 
along with delivering adequate amounts of lipase to the 
duodenum at the same time as the ingested food, microsphere 
technology should allow more adequate mixture with the 
postprandial chyme.3 Studies of labeled capsules suggest 
that even with varying sizes of microspheres, the ingested 
lipid may enter the duodenum in advance of the pancreatic 
enzyme. When, where and at how much enzyme is released 
is not very well studied in humans.110 The new FDA rules in 
terms of pancreatic enzyme replacement therapy (PERT) have 
instructed companies to set up clinical trials in order to fill this 
gap. The results of recent studies of delivery of pancrelipase 
should be informative and could help to ameliorate coating 
materials (ClinicalTrials.gov NCT00676702, Pancrease 
MT, Johnson & Johnson Pharmaceutical, NJ, USA; 
NCT00744250, Pancrecarb MS16, Digestive Care, PA, USA; 
NCT00559052, Viokase 16, Axcan Pharma, Canada).
Currently, the main formulations are immediate-release, 
enteric-coated microspheres and minimicrospheres, 
enteric-coated microtablets, and enteric-coated microspheres 
with a bicarbonate buffer. A comprehensive table of these Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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medications has been summarized in other reviews.3,76 
A major focus of regulation of these products has been on 
the active enzyme content and accuracy of packaging. While 
instability of the enzymes results in delivery medications 
that contain less than the packaged amount of enzyme, 
the practice of “overfilling” in an effort to address enzyme 
degradation may result in excess enzyme content, resulting 
in formulations that deliver inadequate or excess amounts 
of enzyme. In Europe, historically these products have been 
regulated, resulting in more standard enzyme content. In the 
United States, until recently, because of lack of stringent 
regulation, studies showed marked variation in the enzyme 
content of the various formulations, generic products being 
of greatest concern.111 The marketing of products containing 
pancreatic enzymes extracted from animal tissue preceded 
the creation of the FDA in 1938, so that these products 
were historically not regulated by the FDA. In 2004, in 
response to concerns FDA issued a statement requiring that 
all manufacturers of PERT submit New Drug Applications. 
Eventually, the FDA set a deadline of April 28, 2010 for 
approval of all pancreatic enzyme products, and at the time 
of submission of this article, only 3 pancrelipase preparations 
have been approved for use in the United States:112 Creon 
(Abbott, IL, USA), EUR-1008 or Zenpep (Eurand, Milan, 
Italy), and Pancreaze (Johnson & Johnson, NJ, USA). 
All these formulations have been demonstrated to be safe and 
effective in improving lipid malabsorption and the symptoms 
of maldigestion. The most studied of the approved enzymes, 
Creon, is an enteric-coated formulation of pancrelipase 
delivered in the form of minimicrospheres.113–115 Zenpep 
is an enteric-coated bead preparation.116 To counteract the 
problem of non-uniform drug delivery raised by the FDA, 
this formulation of pancrelipase enteric-coated microtablet 
is manufactured with label-claimed lipase content being 
zero-overfilled.116 Clinical Phase III trials demonstrated an 
improvement in coefficient of fecal fat absorption (CFA) 
(88.3% vs 62.8% in placebo group) and lipid-soluble vitamin 
levels.116 Pancreaze is an enteric-coated microtablet.112
In Europe availability of preparations varies by country 
and they are regulated nationally and not by the European 
Medicines Agency. Many regulatory agencies provide 
information on their website and information on available 
enzyme preparations may be sought through the national 
regulatory agency, the pharmaceuticals, or pharmacy 
references. In products in which the enzyme content has been 
standardized, there is still a marked variability in particle 
size, release, and, for some, acid stability, which may result 
in differences in clinical effect.106,117,118
Dosing and schedule of administration
The typical indications for starting enzyme replacement 
therapy are progressive weight loss and steatorrhea, defined 
as at least 7 to 15 g of fecal fat per day, but there are no 
substantial data to support these guidelines. Since steatorrhea 
does not typically occur until .90% of pancreatic lipase 
activity is lost, 10% enzyme activity is the initial goal for 
therapy. Dosing is adjusted based on the amount of lipase in 
the supplements, and the initial dose aims at supplying 40 to 
60 IU/minute of lipase activity within the duodenal lumen. To 
achieve this goal in adults, approximately 25,000 to 40,000 IU 
of lipase is required to digest a typical meal, and about 5000 to 
25,000 IU of lipase per snack. However, is not recommended 
to exceed 10,000 IU of lipase per kg of body weight per 
meal.3,5,71,76 Pediatric dosing is detailed in the products’ 
respective package inserts. Ultimately 50,000, 100,000 and 
150,000 IU of lipase per day will decrease steatorrhea by 45%, 
60%, and 70%, respectively.119 Ideally the correct amount of 
lipase should be divided and administered through the course 
of a meal or immediately after a meal, and dose adjustments 
made after several days to allow for sufficient time for the 
enzymes to work.5 A recent study compared three different 
administration schedules using enzyme replacement before 
meals, during meals, or after meals. It was found that lipid 
digestion was better when giving enzymes during or after 
meals, and patient preference did not differ.120 Currently, 
none of the approved enzyme supplements are specifically 
designed for administration via percutaneous gastrostomy 
tubes. In patients who cannot swallow large capsules, and 
infants, opening the capsules into a small amount of acidic 
food (ie, apple sauce) is an acceptable way to administer the 
medication.
Monitoring therapy
Currently there are no guidelines in clinical practice for 
monitoring the efficacy of enzyme replacement therapy 
and determining a need for dose adjustment. In research 
studies, a commonly used method to monitor therapy is the 
use of the CFA and coefficient of nitrogen absorption. The 
CFA uses a 72-hour stool collection comparing the amount 
of lipid ingested with that excreted.121–123 The cumbersome 
nature of stool studies limits their use in the outpatient 
setting. Commonly, determining the efficacy of therapy is 
performed by clinically assessing the patient’s weight loss 
or gain and diarrhea. Unfortunately, clinical assessment 
correlates poorly with the patient’s nutritional status.124,125 
In a recent study, approximately two-thirds of the study 
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deficiencies as measured by retinol-binding protein, ferritin, 
and pre-albumin. The authors concluded that monitoring 
of weight loss and diarrhea is an inadequate measure of 
nutritional deficiencies in EPI.126 Various breath tests have been 
developed, using various substrates labeled with 13C including 
mixed triglycerides, triolein, and cholesteryl octanoate.127–129 
As an example, the 13C-labeled mixed triglyceride breath test 
uses a labeled substrate with two molecules of stearic acid 
and octanoic acid. Lipolysis is associated with measured 
release of labeled carbon dioxide.130 This test was shown to 
be accurate in estimating pancreatic exocrine function and 
has been shown to correlate with nutritional markers when 
estimating response to enzyme supplementation.131,132 Because 
stool collection is often time consuming and difficult, and 
breath tests are not readily available in all locations or fully 
validated as a clinical tool, following patients clinically is the 
common approach in determining the efficacy of PERT. As 
the degree of symptoms and symptom improvement do not 
always correlate with the patient’s nutritional status, in the 
future we would hope for more clinically relevant and widely 
available tests to monitor therapy, most likely in the form of 
a breath test or a spot stool test.124–126
Efficacy
Although the efficacy of enzyme replacement therapy is 
presumed, the data are not as robust as one might hope. 
Although numerous studies have evaluated the response to 
treatment for outcomes such as steatorrhea and fecal fat, 
surprisingly few have studied improvement in nutritional 
status, even in weight gain.2,113–116,122,133 Enzyme supplements 
have been found to improve lipid malabsorption compared 
with placebo in numerous trials, for both adults and 
children younger than 7 years old.2,113–116,122,133 They have 
also been shown to improve symptoms related to pancreatic 
insufficiency such as abdominal pain, flatulence, stool 
consistency, and improve overall global impression of disease 
symptoms.113 A systematic review of the randomized trials 
of PERT identified only two studies that evaluated weight as 
an outcome, and the difference was not significant.134 It has 
been reported that in patients who were considered to be on 
acceptable replacement therapy, with reduction in steatorrhea, 
markers of significant malnutrition still persisted as measured 
by retinol-binding protein, transferring, and prealbumin.126 
In a prospective, non-placebo controlled study, this group has 
also reported that increasing enzyme therapy to normalize 
13C-mixed triglyceride breath test did significantly improve 
key markers of nutritional status at 1 year.132 As such, although 
it is presumed, the reduction in stool fat achieved by PERT has 
not been proven by rigorous research to be correlated with a 
complete correction of nutritional deficiency in patients with 
pancreatic insufficiency, preventing our overall assessment 
of the efficacy of this therapy. In the future, demonstration 
of long-term outcomes would also be of interest.
Safety and side effects
In general, PERT is regarded as safe with few side effects, 
and adverse events are comparable to those with placebo.2 
Supplemental enzymes act within the lumen of the intestine, 
and this is considered an intraluminal and not a systemic 
therapy. The most commonly reported side effects for recently 
approved enzymes are headache (6%), dizziness (6%), 
abdominal pain (9%), and flatulence (www.micromedex.com). 
Historically, hyperuricemia, and hyperuricosuria, which 
leads to dysuria and uric acid crystaluria, have been reported 
in cystic fibrosis patients with older formulations.135 Folic 
acid deficiency has been associated with use of pancreatin 
extracts which may form insoluble complexes with folate.76 
Irritation of the oral mucosa may be avoided by not chewing 
the medications, or mixing them in foods with a pH . 4.5 
(package inserts). A theoretical risk exists of xenotic viral 
infections, although such cases have not been reported. As 
more concern is focused on the effect of pthalates, which 
are commonly present in the polymer coating, the impact of 
this component will likely be evaluated further.136 The most 
concerning adverse effect associated with enzyme replacement 
is fibrosing colonopathy, which has been described in cystic 
fibrosis patients receiving .24,000 IU of lipase/kg daily.137,138 
It results in submucosal collagen deposition with fibrosis 
and varying degrees of stricturing. Some studies suggest 
that the acid-resistant coating of enzyme preparations may 
be responsible for the fibrosing colonopathy, as it has also 
been demonstrated with other medications that use the 
same methacrylic copolymer coating.76,139–143 In addition, as 
these cases largely occurred with high-dose enzyme therapy 
(.50,000 IU/kg daily), limits are suggested for maximum 
dosage and delivery. Caution should be used when doses 
exceed 2500 IU/kg per meal. Most formulations are considered 
pregnancy class C, as there are insufficient data to evaluate 
their safety, and no data are available on their secretion in 
breast milk.
Treatment failure
Despite optimal dosing of enzymes and clinical assessment, 
treatment failures are common. A systematic approach is 
beneficial in determining the reason for treatment failure 
(Figure 1). The first step is to assess compliance, diet, and Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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timing of administration. Studies have demonstrated that 
efficacy is maximum if medications are taken during and after 
a meal, and such a schedule may need to be detailed with the 
patient.5,120 Although wide variation has been noted between 
products,106,107,111 at this point there is inadequate information 
to recommend changing formulation if the medication is not 
working, although this is not an unreasonable practice, given 
the fact that there are documented differences in delivery and 
release among the marketed products.117,118 Certainly, in areas 
in which generic medications are available, if the medication 
loses its clinical effect in an individual, it should be determined 
if the medication has been changed to a generic form, and 
changed to brand name medication if appropriate. If compliance 
is in question, a fecal chymotrypsin test can be performed to 
confirm compliance. If these possibilities are eliminated as 
primary causes of loss of clinical effect, and secondary causes 
of diarrhea are less likely by history and exam, the first option 
is to increase the amount of lipase given to see if response 
improves. If this is not successful, dietary habits may need 
modification, in particular, a reduction in lipid intake to 50 
to 75 g per day.71 Other treatment modifications may include 
reduction in fiber intake, avoidance of alcohol, and minimizing 
calcium- and magnesium-containing antacids, as these can 
all increase steatorrhea. The next step is usually to administer 
acid-suppressing medications, either histamine-2 receptor 
blockers or proton pump inhibitors. Studies have shown 
improved lipid digestion and absorption with administration 
of acid-suppressing medications to nonenteric-coated 
formulations.144–146 Furthermore, it has been shown that acid 
suppression in addition to enteric-coated formulations will 
improve steatorrhea, and may enable the use of lower amounts of 
lipase.147 Finally, if all the above steps fail, diagnostic evaluation 
for other etiologies for continued steatorrhea is warranted, 
including small intestinal bacterial overgrowth, giardiasis, blind 
loop syndrome, and other absorptive problems.37,71,76
Future developments for an  
optimal therapy
The challenges of current obstacles  
to effective therapy
Optimal lipid digestion and absorption is not always reached 
in EPI patients, which is assumed to be due largely to 
problems with delivery of active lipases at the appropriate 
intestinal site (duodenum) and time of delivery. Also, the 
amount and the type of enzymes administered fails to mimic 
normal human pancreatic secretion that is specific to age and 
to each individual. Treatment requires intake of multiple 
capsules and is expensive. Problems of allergy to porcine 
proteins and religious or other cultural concerns with the 
use of pork products also have to be taken into account. 
To address these issues, ongoing research is focusing on 
identifying new enzyme sources, more efficacious lipases, 
and strategies to enable improved delivery throughout the 
digestive process. Standardized, rapid, in vitro test systems 
to measure the efficacy of such lipases in near physiologic 
conditions need to be set up for screening and to help create 
more accurate PERT product labeling.
Supplementation of duodenal bicarbonate
Acidic degradation of exogenous pancreatic lipase and 
the discrepancy between an optimal pH for enzyme action 
and the actual intra-duodenal pH in EPI patients are major 
factors that prevent complete correction of steatorrhea.71 
One answer is to increase the local duodenal pH. The use of 
sodium bicarbonate (1.34 g per test meal) with enteric-coated 
tablets of pancreatic enzymes combined with desiccated 
ox bile (50 mg per test meal) considerably improved lipid 
digestion as measured by breath-test in patients with chronic 
pancreatitis, without concurrent acid-suppressive therapy.148 
More recently, the effect of administering enteric-coated 
buffered pancrelipase microspheres (Pancrecarb MS-8, 
Digestive Care Inc, PA, USA) containing 2.5 mEq149 or 
1.5 mEq150 of bicarbonate per capsule was tested on CFA 
in CF patients. In both studies, the number of patients, lipid 
consumption, stated lipases units/kg per day (about 4400 
USP) were similar, and patients were their own controls. 
A significant increase in CFA (9%) was observed only in the 
study providing the higher amount of sodium bicarbonate 
(about 6.9 g daily versus 3.1 g daily).149 The results of these 
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Figure 1 Failure of pancreatic enzyme therapy: a systematic approach. 
Notes: *Restrict fat intake to 50–75 g/day, reduction in fiber, alcohol, calcium and 
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studies are difficult to interpret, as individual responses 
to the buffered PERT varied widely, probably because CF 
patients can secrete either normal or high levels of gastric 
acid postprandially.98,151 As a result, there would be marked 
individual variability in duodenal pH as a response to the 
amount of bicarbonate provided.
Alternative sources of lipases
In order to avoid the short half-life of lipolytic enzymes of 
pancreatic origin for replacement therapy, a variety of lipases 
have been tested from sources as diverse as animal gastric 
lipase and microbial or plant lipases.
Supplementation with gastric lipase has been evaluated 
because of the natural acid-resistant properties and broad 
pH of action (3 to 6) of the enzyme.51,152 A dog recombinant 
lipase, rGL, was produced to test this concept153 and was 
developed by the French company Meristem Therapeutics 
SA, Clermont-Ferrand (Merispase), that went out of business 
in September 2008. This approach is problematic for several 
reasons: gastric lipase specific activity is about 10 times lower 
than that of pancreatic lipase (measured on tributyrin);51 it 
is highly sensitive to trypsin proteolysis;154 and endogenous 
secretion of gastric lipase can be increased in patients with 
pancreatic insufficiency28 because of possible nutritional 
adaptation.98,155 However, gastric lipase supplements may 
still be a viable option. Indeed, during gastric lipolysis, 
endogenous human gastric lipase is rapidly trapped within 
fatty acid-rich particles generated at the surface of the 
lipid droplet and is no longer able to access its substrate.156 
The addition of an extra dose of gastric lipase through 
supplementation will allow lipolysis to continue.156 Also, in 
vivo specific activity of gastric lipase can be close to that 
of pancreatic lipase especially on a solid food matrix.38 Two 
clinical trials conducted in CF patients showed that rGL is 
well tolerated and efficient when administered at the dose 
of 600 mg alone, or when associated with pancreatic extract 
(PE) ($300,000 UPS total per day). This combination led to 
a significantly increased CFA compared with PE alone (84% 
vs 71%) in 7 of 11 patients.157 Another study showed that 
250 mg rGL combined with a low dose of pancreatic extract 
led to at least equal CFA compared with a high dose of PE.158 
Furthermore, there was a greater benefit in CF patients with 
low CFA, which also improved quality of life.158
Microbial lipases of fungal or bacterial origin are of 
potential interest because of their acid and protease-stable 
properties and their activity at pH 3 to 10. Rhizopus 
arrhizus,159 Candida cylindacea, Aspergillus niger,160,161 
and Yarrowia lipolytica162,163 are some examples of the most 
tested fungi. The Aspergillus and Yarrowia species have better 
survival in the duodenal environment as shown in vitro and 
in rats, while the others appeared very sensitive to trypsin 
and to the detergent action of bile salts. Lipases derived from 
bacteria are more promising as they are highly resistant to 
both acid and alkaline inactivation, stable in the presence of 
both proteolytic enzymes and bile salts, and active without 
the need for bile salts and colipase.164 A novel, experimental 
type of enzyme supplement containing bacterial lipase, 
fungal protease, and amylase (TheraCLEC-Total or ALTU-
135, Altus Pharmaceuticals, MA, USA) has demonstrated 
good tolerance and efficacy (20% increase in CFA).164 A 
Phase II clinical trial showed that a moderate dose (25,000 
USP of lipase per meal) resulted in a 35% to 40% increase 
in the CFA of cystic fibrosis patients with 0% to 40% CFA at 
baseline, and that a high dose (100,000 USP lipase per meal) 
was necessary for a 10% increase in the CFA of patients with 
41% to 80% baseline CFA, after 1 month’s treatment.165 A 
1-year, multi-center, Phase III clinical trial was completed 
in 2009 (ClinicalTrials.gov NCT00500084) and results are 
pending.166 Thus, Liprotamase (formerly known as ALTU-
135 and Trizytek), for which a pediatric formulation is in 
progress, is the first porcine-free PERT developed since the 
end of 2008 (Alnara Pharmaceuticals, MA, USA, acquired 
by Eli Lilly, IN, USA).167 A better knowledge of the microbial 
lipases structure and modes of action will probably help to 
select and design much more active enzymes in the near 
future.168,169
Plant acid-stable lipase, as in oats,170 and plant latex 
lipase extracts from euphorbia characias, fruit of babaco, or 
carica papaya171,172 are potential sources of lipases. At this 
point, kinetics have been studied only in vitro and scientific 
data are needed on their digestive function in physiological 
conditions.
Recombinant human lipases
Recombinant human lipases would be expected to offer 
superior safety by decreasing the risk of allergic reactions. 
Progress in protein engineering173 and a detailed knowledge 
of human lipases174 will enable large-scale production and 
the ability to apply directed mutagenesis if necessary for 
improving lipase stability and activity in acidic conditions. 
Of note, the use of recombinant human lipases may be 
limited by the fact that changes in glycosylation (rates 
and type) and other post-translational modifications in 
proteins produced in the non-eukaryotic cell system used 
for large-scale production may interfere with enzymatic 
activity.175,176Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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A promising candidate for the treatment of lipid 
malabsorption is a recombinant human bile salt-stimulated 
lipase (rBSSL). This enzyme is naturally acid resistant and 
able to hydrolyze triglycerides and phospholipids.59 Two 
preparations dedicated to cystic fibrosis patients and preterm 
infants, Exinalda and Kiobrina, respectively, are currently 
under development (Biovitrum AB, Stockholm, Sweden). 
A Phase I clinical trial was conducted in 9 CF patients with 
EPI, measuring lipid uptake through breath-test.177 The 
addition of rBSSL (0.2 or 1 g) to standard pancrelipase 
(Creon) enabled a dose reduction of pancrelipase to 25% of 
normal dose.177 Plasma chylomicron level was significantly 
higher with the addition of rBSSL (34% to 48%), a clear 
secretion peak being reached at 3 hours after the meal,177 
which is similar to the pattern found in normal subjects,30 
while no real peak was observed with pancrelipase dosing 
alone. This can be explained by the ability of BSSL to generate 
lysophospholipids necessary for an efficient lipid absorption 
rate by the small intestine,61 and to participate in chylomicron 
assembly and secretion through its ceramidase activity.14 
Another study was conducted through 2009 with Exinalda 
in 18 CF patients with EPI in Poland and the Netherlands, 
but the results have not yet been published (ClinicalTrials.
gov NCT00743483). Two Phase II clinical trials have been 
conducted in Italy and France with Kiobrina administered at 
a dose physiologically found in human milk (0.15 g/L) for 
1 week to premature infants in formula (ClinicalTrials.gov 
NCT00658905) or in pasteurized breast milk (ClinicalTrials.
gov NCT00659243), but results are not yet available.
Directional mutagenesis and use of electrostatic 
computations has also allowed generation of a human 
pancreatic lipase with modified pH of action (pH 4–5).178 
Pancreatic lipase is irreversibly inactivated by gastric acid 
at a pH of 4.0 and below and its activity is very low at pH 
5.0.10 Several variants of the recombinant human pancreatic 
lipase were generated by error-prone PCR and screened for 
stability and activity at a pH of 5 in vitro.179 Although these 
enzymes were more acid stable, their activity on physiologic 
substrates was not enhanced compared to native human 
pancreatic lipase.
Delivery system strategies
Bacterial engineering and gene transfer techniques could 
revolutionize the delivery of pancreatic enzymes by 
producing the enzymes within the host. Strains of bacteria 
such as Lactococcus lactis, genetically modified to highly 
express bacterial lipases, have been derived.180 Colonization 
of pigs with experimentally induced pancreatic insufficiency 
with lipase-producing L. lactis demonstrated increased 
CFA under a high-fat diet.181 The treatment occurs as the 
bacteria release their cellular content in response to contact 
with proteolytic secretions and bile acids.181 A gene therapy 
approach could be envisioned as an alternative therapeutic 
strategy to improve lipid digestion and absorption in EPI 
patients by mediating enzyme production by transduced cells 
within the treated patient. Indeed, the human pancreatic lipase 
gene has been successfully expressed in the biliary tract in 
rats using recombinant adenovirus.182
Strategies through substrate 
physicochemical properties and lipase 
activators
As an alternative, creating functional dietary lipids that are 
more effectively digested is another frontier of treatment 
for pancreatic insufficiency. Triglyceride digestion is more 
efficient when the substrate is emulsified, ie, dispersed, in 
aqueous medium as lipid droplets which consist in a core 
of triglycerides stabilized by a layer of phospholipids or 
other emulsifiers. The process of emulsification creates a 
lipid–water interface allowing optimal action of lipases.183 
The physicochemical properties of such an interface can 
modulate the rate of lipolysis.183,184 Thus, structuring food 
emulsions is a new concept that should improve lipid 
digestion and absorption in EPI patients by selecting the 
best lipid physicochemical properties for optimal action of 
lipases.28,30,185,186
Lipid droplet size is one of the key physicochemical 
parameters of triglyceride digestion by gastric and pancreatic 
lipases, as it governs the lipid–water interface area.29,30,155 
Droplet size is inversely related to the lipid interface area, and, 
theoretically, small-sized droplets should be more efficiently 
digested in the digestive tract offering a larger interface area 
that will allow the binding of more lipase molecules at the 
interface. Indeed, it was shown in healthy humans that the 
triglycerides from small-sized droplets (0.7 µm) are more 
efficiently digested in the stomach and in the duodenum than 
from larger droplets.30 Even though this has a potential for 
health, it has not been tested yet in EPI patients.
Another physicochemical key factor involved in lipid 
digestion is the ultrastructure, ie, droplet surface layer 
composition (phospholipid classes, phospholipid fatty acid 
profile, adsorbed proteins).184 Lipases bind to such a surface 
layer to access to triglycerides contained in the core of the 
droplet. The composition of the droplet surface layer plays 
a key role in vivo as it was shown that native human milk 
droplets of about 4 µm (three phospholipid layers) were Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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more efficiently lipolyzed in the stomach of premature 
babies than small-sized droplets (0.5 µm) from a formula 
(single layer).56 It was shown in vitro that specific classes of 
phospholipids will prevent pancreatic lipase activity,187 or 
enhance dramatically gastric lipase, pancreatic lipase, and 
BSSL activity in conditions that mimic physiology.188,189 Also, 
the dietary protein interaction within the droplet surface can 
improve or diminish the triglycerides lipolysis rates.190
A third physicochemical property of lipids that is of 
particular importance in patients suffering from digestive and 
absorptive disorders is the triglyceride structure, ie, the nature 
of fatty acid esterified at positions sn-1, sn-2, and sn-3 of 
the glycerol backbone.191–194 Indeed, this structure influences 
digestion, as the lipolysis rate depends on the type of fatty acid 
present at the sn-1 and sn-3 positions,195 and the lipid droplet 
size can differ depending on the triglyceride structure.196 
Triglyceride structure also affects i) the absorption step, 
as the fatty acid is better absorbed when it is present as a 
2-monoglyceride;193,197,198 ii) the enterocyte re-synthesis step 
and the secretion of chylomicrons by the enterocyte, as the 
fatty acid of the sn-2 position is retained in chylomicron 
lipid particles; and iii) the lipid metabolism.198,199 So, the 
structure of triglycerides is particularly important to improve 
absorption of essential and very-long chain fatty acids.193,200 
In contrast, absorption of long-chain saturated fatty acids can 
be dramatically decreased when present at the sn-1 and sn-2 
positions of the triglyceride molecule and in the presence 
of high concentration of calcium or magnesium, because 
they form insoluble soaps.197 Except for Betapol (Lipid 
Nutrition, Hogeweg, the Netherlands) used in several milk 
substitutes because it is a source of structured triglycerides 
with long-chain saturated fatty acids in sn-2 position, as in 
human milk,192,193 other kinds of structured triglycerides are 
not often used, probably because of their cost.193
Functional foods are a new area of research for clinical 
nutrition. For EPI patients, specific, more digestible or 
absorbable lipid sources could be designed. The addition 
of specific phospholipids able to enhance lipase activity in 
enzyme supplements or in formula would both increase lipase 
activity and, in parallel, enhance lipid nutrient absorption.
Conclusion
Exocrine pancreatic insufficiency results from a wide range 
of medical and surgical conditions. PERT is the standard 
treatment for the resultant malabsorption. Therapy is in 
general well tolerated and efficacy is satisfactory. Although 
progress has been made in standardizing therapy and 
improving enzyme formulations, there is still room to improve 
in terms of fully resolving the symptoms and malnutrition 
related to EPI, along with convenient and accurate means 
for monitoring therapy. In the clinical setting, a basic 
understanding of the physiology of enzyme delivery assists 
in choosing, monitoring, and adjusting therapy. Currently the 
most common monitoring strategy is clinical response, as 
stool fat and breath testing are cumbersome and less clinically 
available. Dose adjustments can be made according to the 
amount of steatorrhea and the patient’s weight loss or gain. 
The common problem of incomplete response to therapy 
might also indicate that the mechanism of malabsorption 
in pancreatic insufficiency is more complex than simply a 
lack of pancreatic enzymes and electrolyte secretions, and 
further study in this area is warranted. In the future, with the 
advent of new technology, we look forward to delivering even 
better tolerated replacement therapy, which replicates more 
accurately the function of the native pancreas or delivers 
nutrition more effectively, and more convenient or available 
means of monitoring therapy.
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